key: cord-0794914-yd4ook8b
authors: Li, Ying; Harunori, ODA; Fu, Shihu; Xing, Fuyuan; Wu, Huawan; Wang, Juan; Chen, Aihua; Ren, Xinhua; Peng, Dawei; Ling, Xia; Shi, Ming; Wu, Hongjin
title: Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells
date: 2021-08-30
journal: Aging (Albany NY)
DOI: 10.18632/aging.203279
sha: 3747fa8deb27e50f5087c124d2a8b062de60f2ca
doc_id: 794914
cord_uid: yd4ook8b

“Immune normalization” has emerged as a new paradigm in immunotherapy, which is proposed in cancer patients instead of conventional “immune-enhancement” therapy. Immune normalization may also be implemented in cancer prevention of “sub-healthy” individuals. We established in vitro cultured mixed-natural killer (NKM) cells to achieve immune normalization. The in vitro cytotoxicity of NKM cells was tenfold higher than that of peripheral blood mononuclear cells (PBMCs). The cytotoxicity of NKM cells was negatively correlated with the proportion of T-helper cells (cluster of differentiation: CD3+CD4+ T), and positively correlated with the proportion of NK cells (especially CD56(bright)CD16(bright) NK cells). Then, we defined “sub-healthy individuals” after measuring Programmed cell death protein-1 (PD-1) expression in PBMCs from 95 donors aged > 50 years. Furthermore, we evaluated the potential clinical application of NKM-cell therapy in 11 patients with malignant lymphoma, one patient with pancreatic cancer, and four sub-healthy individuals. NKM-cell therapy elicited good tolerance and side-effects were not found. In sub-healthy individuals, the proportion of CD3(+)PD-1(+) T cells and CD3(+)CD8(+)PD-1(+) T cells was reduced significantly after NKM-cell treatment. We demonstrated that a new method using NKM cells was safe and efficacious as adjuvant treatment for cancer patients as well as therapy for sub-healthy individuals. Normalization of the peripheral immune system through NKM-cell therapy could expand its scope of application in different disorders.

The immune system is a crucial barrier for the human body to resist diseases. Its ability has rhythmic fluctuations [1, 2] , and is affected by several factors (e.g., genetic, age [3, 4] ). Reduction in the response capacity of immune cells can lead to diseases (e.g., cancer), whereas excessive activation of immune cells can cause autoimmune diseases. Thus, balance in the immune system is important for health [5] .

In recent decades, epidemiological data for colorectal cancer and lung cancer have revealed that prevention and early detection of cancer are far more efficacious than their treatment for controlling cancer mortality [9, 10] . Application of immune-cell therapy in disease prevention (especially cancer) can greatly reduce the occurrence or relapse of diseases [11, 12] . For older individuals who may have long-term immunocompromise, immune-cell therapy could "rebalance" their immune system, which would eliminate mutant cells and pathogens (e.g., viruses, bacteria), thereby reducing the disease risk.

Expression of programmed cell death protein (PD)-1 on T cells has been considered a sign of "immune exhaustion" [13, 14] . PD-1 expression on peripheralblood mononuclear cells (PBMCs), including cluster of differentiation (CD)4 + and CD8 + T cells, has been shown to be increased significantly in cancer [15] [16] [17] [18] [19] [20] , sarcoidosis [21] and chronic infection with the hepatitis-C virus [22] . In 2019, Cortese and colleagues found that in progressive multifocal leukoencephalopathy, PD-1 expression on PBMCs was high and could be reduced significantly after pembrolizumab treatment [23] . Furthermore, in patients suffering from severe coronavirus disease 2019 (COVID- 19) , in addition to a reduction in the number of peripheral-blood T cells [24] [25] [26] [27] [28] , the proportion of PD-1 expression in the remaining T cells is very high [27, 28] .

We established an in vitro cultured mixed-NK (NKM) cell system using PBMCs and then tested its potential anti-tumor activity in vivo and in vitro. Our data represent the first NKM-cell therapy, and could be used for healthcare and, possibly, cancer treatment.

To achieve safe and efficacious immunotherapy for patients, we established an in vitro culture system for the production of immune cells without separation or biological additives. The medium used in this culture system was designed specifically for the expansion of NK cells and T cells. Autologous plasma was prepared and inactivated, then used for cell culture. Autologous immune cells were manufactured as shown in Figure 1A and in the Methods and Materials section: these were NKM cells. After the culture was complete, we could obtain ~2.5 billion immune cells, the main components of which were NK cells and T cells.

We analyzed the immune-cell subsets of NKM cells. The proportion of monocytes (CD14 + ), B cells (CD19 + ) and dendritic cells (CD11c + ) was extremely low. In total, 369 NKM cells were analyzed for the distribution of NK cells (CD45 + CD3 − CD16/56 + ) and T cells (CD45 + CD3 + ). NKM cells comprised ~20% NK cells (CD3 − CD16/56 + ),  ~30%  NK  T-like  cells  (CD3 + CD16/56 + ) , and other T cells. Of the T cells within NKM cells, ~30% were T helper (T h ) cells (CD3 + CD4 + ) and 50% were cytotoxic T cells (CD3 + CD8 + ) ( Figure 1B ). In PBMCs, NK cells comprised mainly CD3 -CD16 + CD56 neg NK cells and CD3 − CD16 + CD56 dim NK cells (Supplementary Figure  1A) . However, the NK cells from NKM cells mainly comprised CD3 − CD16 + CD56 + NK cells, of which the main subtype was CD3 − CD16 bright CD56 bright NK cells ( Figure 1C and Supplementary Figure 1B) . Furthermore, we analyzed the subpopulations of NK cells from donor-L at different stages of cell culture, including at the primary-culture stage (PBMCs, T75 flask, and T225 flask) and expansion stage (CO 2 Bag). The main subpopulation of NK cells in PBMCs was CD16 bright NK cells ( Figure 1D ). The latter transformed into CD16 dim NK cells upon primary culture ( Figure 1E , 1F), and finally became CD16 bright CD56 bright NK cells after expanded proliferation ( Figure 1G ).

We tested the in vitro cytotoxicity of NKM cells on a cancer cell line (K562), and compared its cytotoxicity with that of PBMCs and NK92 cells. In PBMCs (from healthy donors), the mean cytotoxicity was ~7.4% (effector/target (E/T) ratio = 10:1, 2-h incubation; n = 9) and 16.8% (E/T ratio = 10:1, 4-h incubation; n = 28). The mean cytotoxicity of NKM cells (n = 198) that we manufactured was ~65.6% (E/T ratio = 10:1, 2-h incubation), which was almost tenfold higher than that of PBMCs (Figure 2A and Supplementary Table 1 ). Approximately 84% of NKM cells showed >40% cytotoxicity. Even with more effector cells and longer incubation times, the cytotoxicity of PBMCs remained far inferior to that of NKM cells ( Figure 2B, 2C) . Then, the cytotoxicity of NK92 cells was investigated with different E/T ratios (Supplementary Figure 2A) . We discovered that the cytotoxicity of NKM cells (E/T ratio = 10:1) was comparable with that of NK92 cells, with an E/T ratio of 5:1 (2-h incubation) (Supplementary Figure 2B ). Taken together, these results suggested that, although NKM cells had only half the cytotoxicity of that observed in "pure" NK cells (NK92), their cytotoxicity was much higher than that of PBMCs.

NKM cells are a mixed population of cells, so we wondered which subsets of these cells were responsible for in vitro cytotoxicity. We analyzed the subpopulations of NKM cells, and undertook correlation analyses of their in vitro cytotoxicity. We separated AGING NKM cells into NK cells (CD3 − CD16 + or CD56 + ), NK T-like cells (CD3 + CD16 + or CD56 + ), CD4 T cells (T h cells, CD3 + CD4 + ) or CD8 T cells (cytotoxic T cells, CD3 + CD8 + ). A strong positive correlation was observed between the cytotoxicity of NKM cells and the proportion of NK cells (r = 0.58, p < 0.0001), but a negative correlation with the proportion of T h cells was noted (r = −0.32, p < 0.0001) ( Figure 3A , 3C). There was no correlation with the proportion of NK T-like cells and cytotoxic T cells ( Figure 3B , 3D).

Furthermore, we divided NK cells into three subpopulations: CD56 + CD16 − NK cells, CD56 + CD16 + NK cells, and CD56 -CD16 + NK cells. The cytotoxicity of NKM cells showed a significant correlation only with CD56 + CD16 + NK cells (r = 0.56, p < 0.0001), and no correlation was found in CD56 + CD16 − NK cells or CD56−CD16 + NK cells ( Figure 3E -3G). Then, we used sorting of immunomagnetic beads to separate different cell subpopulations in NKM cells, and verified them with flow cytometry. We discovered that NK cells isolated from NKM cells showed the highest cytotoxicity ( Figure 3H ), CD3 − cells, CD4 − cells and CD8 − cells showed moderate cytotoxicity, and NKnegative cells, CD3 + cells, CD4 + cells, and CD8 + cells showed the lowest cytotoxicity (Supplementary Figure  3A -3C).

In addition, we studied the secretion of cytokines in these NKM cells: interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (INF)-ɣ. The media from 10 cultured NKM cells were collected and analyzed. The concentration of IL-4, IL-6, IL-10 and TNF-α was very low (<100 pg/mL), whereas the INF-ɣ concentration was very high (~300 pg/mL on average) (Supplementary Figure 4) .

Taken together, these data suggested that the in vitro cytotoxicity of NKM cells was caused mainly by the cytotoxicity of CD56 + CD16 + NK cells, and was suppressed by T h cells.

After the characterization of NKM cells, the potential in vivo anti-tumor activities of NKM cells were investigated in cancer patients for adjuvant cancer therapy. We recruited 11 patients with malignant lymphoma (diffuse large B-cell lymphoma [seven patients], peripheral T-cell lymphoma [two patients], anaplastic large-cell lymphoma [one patient], and Hodgkin's lymphoma [one patient]) who suffered primary relapse/were refractory to treatment (one patient), relapsed after salvage chemotherapy (eight patients), or relapsed after autologous stem-cell therapy (two patients). The treatment process is shown in Figure  4A . Each patient received an intravenous injection of 20-30 ×10 8 NKM cells each time (treatment once every 2 weeks). The response to NKM treatment was not robust (a complete response in one case and stable disease in one case) (Supplementary Table 2 ), but quality of life was improved greatly. In the patient who had a complete response (case #2), the number of AGING cancer foci was reduced significantly after treatment with NKM cells ( Figure 4B ). During and after intravenous infusion of NKM cells, the body temperature, blood pressure, and heartbeat remained stable, and adverse reactions were not found. The patients tolerated the treatment and clinical side-effects were absent.

Systematic reviews of therapy with NK cells have indicated that immunotherapy with allogeneic NK cells AGING has better clinical efficacy than that using autologous cells [29] [30] [31] . Thus, we recruited another patient with pancreatic ductal carcinoma (T4N1M1c) whose cancer cells had metastasized, and he could not sustain chemotherapy. Then, we treated this patient with a human leukocyte antigen-matched infusion of haploidentical NKM cells (donor was the patient's son). The patient received an intravenous injection of 20-30×10 8 AGING NKM cells every week. After six treatments, the patient showed good toleration of treatment, and the number of metastatic foci in the renal pelvis and abdominal pelvic peritoneum was reduced significantly ( Figure 4C ). The patient's vital signs and physical status were improved significantly.

Taken together, these results suggested that NKM cells displayed efficacious anti-tumor activity in cancer patients, and suggested that NKM cells could be used for adjuvant cancer therapy.

When analyzing the PBMCs of cancer patients, researchers found that PD-1 expression was significant-ly induced in peripheral immune cells [18, 19, [32] [33] [34] . Previously, we found that among adolescents (10-20 years), the proportion of PD-1 + PBMCs (CD3 + CD4 + PD-1 + or CD3 + CD8 + PD-1 + ) was very low (<2%) (data not shown). However, the proportion of PD-1 + PBMCs in adults varies greatly, and the proportion in individuals is stable if external intervention is not applied. Here, to identify sub-healthy individuals, we measured expression of PD-1 and cytotoxic T lymphocyteassociated protein (CTLA)-4 in the NK cells and T cells of PBMCs in 95 individuals aged >50 years (Supplementary Table 3 ). PD-1 was expressed only on T cells, including T h cells and cytotoxic T cells, but not on NK cells, whereas CTLA-4 was not expressed in any PBMCs ( Figure 5A, 5B) . High expression of PD-1 in T cells may indicate that a large number of T cells are exhausted [13, 14] which, in turn implies an abnormal immune system. 

The proportion of CD3 + PD-1 + cells in PBMCs was usually <4%, and only 16.8% of individuals had >4% of CD3 + PD-1 + cells in PBMCs ( Figure 6A ). The proportion of CD3 + CD4 + PD-1 + cells in CD3 + CD4 + T cells was usually <10%, and only 9.5% of individuals had >10% of CD3 + CD4 + PD-1 + cells in CD3 + CD4 + T cells ( Figure 6B ). The proportion of CD3 + CD8 + PD-1 + cells in CD3 + CD8 + T cells was usually <10%, and 37.9% of individuals had >10% of CD3 + CD8 + PD-1 + cells in CD3 + CD8 + T cells ( Figure 6C ). To define subhealthy individuals, we set the threshold of the ratio of CD3 + PD-1 + cells/PBMC cells to >4% and the threshold of the ratio of CD3 + CD8 + PD-1 + cells/CD3 + CD8 + cells to >10%. Furthermore, we measured PD-1 expression in NKM cells. The proportion of CD3 + PD-1 + cells and CD3 + CD4 + PD-1 + cells was increased in NKM cells, whereas the proportion of CD3 + CD8 + PD-1 + cells was reduced significantly in NKM cells (p < 0.0001) (Supplementary Figure 5) . About 4.2% of individuals in our cohort showed these characteristics, so the immune system of these people may be abnormal, and we defined these people as "subhealthy individuals".

We recruited four potential sub-healthy individuals and the treatment schedule is shown as Figure 7A . Approximately 20×10 8 autologous NKM cells were used for each treatment. Measurement of PD-1 expression in T cells was done before treatment, after the first injection, and after the third injection. In Patient-M and Patient-Z, upon a single injection of NKM cells, PD-1 expression in CD3 + , CD3 + CD8 + , and CD3 + CD4 + cells could be reduced significantly to a normal level (CD3 + PD-1 + cells/CD3 + cells was <4%; CD3 + CD4 + PD-1 + cells/CD3 + CD4 + cells was <10%; CD3 + CD8 + PD-1 + cells/CD3 + CD8 + cells was <10%) ( Figure 7B, 7C) . In Patient-J, the effect of one injection of NKM cells was not obvious. After three injections of NKM cells, PD-1 expression in CD3 + , CD3 + CD4 + , and AGING CD3 + CD8 + cells decreased eventually to a normal level ( Figure 7D ). In Patient-C, three injections of NKM cells reduced PD-1 expression in CD3 + cells and CD3 + CD8 + cells, but not in CD3 + CD4 + cells ( Figure 7E ). All sub-healthy individuals showed good tolerance to treatment, and side-effects were not observed.

In summary, we found that with three therapies with autologous NKM cells, we could reduce PD-1 AGING expression in PBMCs, and achieve renormalization of the immune system in sub-healthy individuals.

For decades, researchers have focused efforts on "enhancing/improving" the immune system to eliminate the potential risks of serious diseases (e.g., cancer). The development of immune-cell therapies have made these concepts a reality.

A safe and efficacious method using NKM cells for the potential adjuvant treatment and prevention of cancer is presented here. We characterized the composition of NKM cells and investigated their cytotoxicity in vitro and in vivo. We showed that NKM cells were significantly cytotoxic to K562 cells or hepatocellular carcinoma cells [35] . However, compared with the number of cancer cells in cancer patients, the number of NKM cells that can reach a cancerous area is relatively small, so the anti-cancer effect is limited. Although the study cohort was and treatment effect was not robust, we showed the potential adjuvant anticancer function of NKM-cell therapy. The latter may not be as efficacious as therapy using pure NK cells. Nevertheless, due to its ease of operation and safety (fewer immune-related side-effects were found), we believe that NKM-cell therapy is potent adjuvant therapy for cancer patients, especially in combination with surgery, to improve the immune response and eliminate residual cancer cells.

Recently, scholars have proposed that cancer immunotherapy should focus on normalization of the immune system [6] . The proportion of PD-1 + immune cells (exhausted immune cells) is increased in the cancer tissues and PBMCs of cancer patients [13, 20, 23] . We postulate that this abnormality in PD-1 expression in PBMCs may be related to a high risk of cancer. A high proportion of PD-1 + T cells in PBMCs was found in some older adults (4.21%) in our cohort. Among the subhealthy individuals defined in our research, NKM-cell therapy could reduce PD-1 expression in PBMCs and quickly restore/rebalance the immune system. However, for some individuals (e.g., Patient C), more injections or larger doses of NKM-cell therapy may be required to reduce PD-1 expression in PBMCs.

We expanded NKM-cell therapy to not only treat cancer patients, but also prevent cancer in patients through normalization of the peripheral immune system. NKMcell therapy for sub-healthy individuals must be studied in randomized clinical trials. Our study could be used as reference to expand the number of applications of immune-cell therapy.

The COVID-19 pandemic is wreaking havoc on healthcare and economic systems worldwide. In patients with severe COVID-19, reduction in the number of immune cells and exhaustion of functional T cells in peripheral blood has been documented [28] . Just like our sub-healthy individuals, PD-1 expression is increased significantly in the CD4 + T cells and CD8 + T cells of PBMCs in COVID-19 patients. Our experiments in sub-healthy individuals normalized their peripheral immune system, so NKM-cell treatment for COVID-19 patients could be possible.

We demonstrated that a new method using NKM cells was safe and efficacious as adjuvant treatment for cancer patients as well as therapy for sub-healthy individuals. Normalization of the peripheral immune system through NKM-cell therapy could expand its scope of application in different disorders.

Medicine in BOAO International Hospital (Qionghai, China). Primary PBMCs were separated from whole blood (30-60 mL). A T75 flask was pre-coated with OKM25 medium (Fukoku, Ageo, Japan). PBMCs from individuals were cultured for 3-5 days in T75 and T225 flasks with OKM100 medium containing 1750 JRU/mL of IL-2 (Fukoku) and 10% autologous inactivated plasma. Then, NKM cells were transferred to a CO 2 Bag containing 1 L of OKM200 medium (containing 175 JRU/mL of IL-2) (Fukoku) and 1% autologous inactivated plasma, followed by culture for 3-5 days. NKM cells were incubated at 37° C in a humidified incubator in an atmosphere of and 5% CO 2 .

The study protocol was approved by the Medical 

The cytokines secreted by NKM cells were analyzed by Human Th1/Th2 Cytokine Kit II (551809) from BD Biosciences. NKM cells (~2×10 9 cells) were harvested from 1.5 L of culture medium. The cytokines in these media were dyed and analyzed by flow cytometry according to the instructions of the CBA-kit supplier. Then, the collected data were analyzed with FCAP Array v3.0 (BD Biosciences).

Experiments were carried out independently in triplicate. Data are the mean ± SD. Graphs were plotted and analyzed with Prism 7.1 (GraphPad, La Jolla, CA, USA). P < 0.05 was considered significant.

All data have been added in the Supplementary Tables.

H.W. and X.L. designed the study. Y.L., S.F., and F.X. 

Circadian Clocks in the Immune System

Clocking in to immunity

Ageing alters the impact of nutrition on immune function

Differences in Cytokine Production during Aging and Its Relationship with Antimicrobial Peptides Production

The managed immune system: protecting the womb to delay the tomb

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Current progress in NK cell biology and NK cell-based cancer immunotherapy

New development in CAR-T cell therapy

Colorectal cancer screening reduces incidence, mortality and morbidity

Low-dose computed tomography screening reduces lung cancer mortality

Characterization of human natural killer cells for therapeutic use

Control of Metastasis by NK Cells

Reversing T-cell Dysfunction and Exhaustion in Cancer

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

PD-1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection

Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity

Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical and immunological features of severe and moderate coronavirus disease 2019

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells

Reduction and Functional Exhaustion of T Cells in Patients

Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer

Repertoire of peripheral T cells in patients with oral squamous cell carcinoma

Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma

Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma

Immune Normalization Strategy Against Suboptimal Health Status: Safe and Effective Mixed-Natural Killer Cell Therapy

The secretion of cytokines in NKM cells. The cytokines: interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (INF)-ɣ were investigated. The media from 10 cultured NKM cells were collected and analyzed

Supplementary Figure 5. The PD-1 expression rate in the subpopulations of NKM cells. The ratio of PD-1 expressing CD3 T cells, CD4 T cells, and CD8

The authors thank Mr. Xianyu Li (Jimin Pharmaceuticals) and Mr. Jianguo Xu (BOAO International Hospital) for providing the GMP Laboratory. This manuscript has been released as a preprint at Research Square (Ying Li et al.) [36] .

The authors declare that they have no conflicts of interest.

This work was supported by grants from the National Natural Science Foundation of China (81903046 and 31870891), and China Postdoctoral Science Foundation (2020M673596XB).